Clinical trials: Gonadal Disorders
Cancer, Cancer in Pregnancy
ProspectiveFemaleAYA - Late Effects of Cancer Therapies on Gonadal Function, Fertility, Efficiency of Fertility Preservation Procedures and Pregnancy Outcomes
In the past two decades, the evidence-based knowledge on the prevalence and risk factors for gonads impairment, including infertility, following cancer and numerous cancer treatment regimen has significantly increased.
- Conditions
- Cancer, Cancer in Pregnancy, Infertility, In Vitro Fertilisation (IVF) Treatment
- Trial name
- FemFertilAYA (NCT07622420)
- Volunteers
- 3,000 people
- Sponsor
- Karolinska Institutet
Sarcoma, Ovarian Neoplasm
Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types
This is a Phase 2, non-randomised, open-label, multicentric study to investigate the efficacy and safety of pembrolizumab monotherapy in 7 cohorts of patients with specific rare cancers who have unresectable locally advanced or…
- Conditions
- Sarcoma, Ovarian Neoplasm, Central Nervous System Neoplasm, Thyroid Neoplasm
- Trial name
- AcSé (NCT03012620)
- Testing
- Pembrolizumab
- Where
- France
- Volunteers
- 334 people
- Sponsor
- UNICANCER
Congenital Adrenal Hyperplasia
Androgen Reduction in Congenital Adrenal Hyperplasia, Phase 1
Children with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency tend to have elevated circulating levels of androgens, which can accelerate skeletal maturation and adversely impact adult height.
- Trial name
- NCT02574910
- Testing
- Abiraterone acetate
- Where
- 4 sites in United States
- Volunteers
- 4 people
- Sponsor
- University of Texas Southwestern Medical Center
Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)
The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of atumelnant treatment in pediatric participants with classic congenital adrenal hyperplasia (CAH).
- Trial name
- NCT07159841
- Testing
- Atumelnant
- Where
- 52 sites in United States, Argentina and 11 more
- Volunteers
- 153 people
- Sponsor
- Crinetics Pharmaceuticals Inc.
Ovarian Neoplasms
MRI in Ovarian Tumors
Role of multi paramrtric MRI and MRI perfusion in indetermint ovarian lesions by using ORADS MRI
- Trial name
- NCT05769205
- Testing
- MRI
- Volunteers
- 25 people
- Sponsor
- Assiut University
Precocious Puberty
Treatment of Boys With Precocious Puberty
This study is a continuation of two previous studies conducted at the NIH. The first study , "Treatment of True Precocious Puberty with a Long-Acting Lutenizing Hormone Releasing Hormone Analog (D-Trp(6)-Pro(9)-Net-LHRH)" had…
- Trial name
- NCT00001202
- Testing
- Spironolactone, Testolactone, Deslorelin
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Infertility and at High Risk of OHSS
Repeated Injection of GnRH Agonist to Reduce Ovarian Hyperstimulation Syndrome
Gonadotropin releasing hormone (GnRH) agonist is sufficient for triggering final oocyte maturation in GnRH antagonist protocol and can significantly reduce incidence of ovarian hyperstimulation syndrome (OHSS) in high-risk…
- Trial name
- NCT02022241
- Testing
- triptorelin
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Chenshiling
Ovarian Neoplasms, Germ Cell Tumors
Immunohistochemical Evaluation of Protein P16 Expression in Ovarian Germ Cell Tumors.
Ovarian germ cell tumors (OGCTs) constitute 10% of ovarian tumors in Egypt and mainly affect young females. Teratomas are the most common type.Most of teratomas is benign. However, it is liable for malignant transformation.
- Conditions
- Ovarian Neoplasms, Germ Cell Tumors, Immunohistochemistry
- Trial name
- NCT04283773
- Testing
- p16INK4a Recombinant Rabbit Monoclonal Antibody (RM267), Ki67 antibody (DAKO) for malignant cases only
- Where
- Egypt
- Volunteers
- 62 people
- Sponsor
- Assiut University
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Capecitabine in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cavity Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of capecitabine in treating patients who have recurrent…
- Trial name
- NCT00006812
- Testing
- capecitabine
- Where
- 31 sites in United States, Canada
- Sponsor
- Gynecologic Oncology Group
Hydrocele, Hydrocele of Tunica Vaginalis
Risk of Scrotal Hydroceles After Nephrectomy For Kidney Cancer
This population-based study will use provincial health administrative data to examine the risk of hospital admission for hydrocelectomy among males who underwent nephrectomy for kidney cancer, compared with males from the general…
- Conditions
- Hydrocele, Hydrocele of Tunica Vaginalis, Hydrocelectomy, Nephrectomy
- Trial name
- NCT07527637
- Testing
- Laparoscopic nephrectomy for kidney cancer, Open nephrectomy for kidney cancer
- Volunteers
- 40,000 people, healthy volunteers welcome
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Cancer
Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation
RATIONALE: Antivirals such as valacyclovir act against viruses and may be effective in preventing cytomegalovirus. It is not yet known if valacyclovir is effective in preventing cytomegalovirus in patients undergoing stem cell…
- Trial name
- NCT00045292
- Testing
- acyclovir, acyclovir sodium, valacyclovir
- Where
- 6 sites in United States
- Sponsor
- Fred Hutchinson Cancer Center
Ovarian Torsion
The Length of Uteroovarian Ligament and the Risk of Ovarian Torsion
Ovarian torsion is one of the gynecological emergency. This complication requires high clinical suspicion and early detection, to prevent permanent loss of ovarian function.
- Trial name
- NCT01880905
- Testing
- Measure of uteroovarian ligament length during gynecological surgery
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Meir Medical Center
Central Precocious Puberty
A Study of Leuprorelin 1-Month (4-Week) Formulation in Children With Central Precocious Puberty
A Single-Arm, Open-Label, Multicenter, Prospective Clinical Study to Evaluate the Effectiveness and Safety of Leuprorelin 1-Month (4-Week) Formulation Administered for 24 Months in Children with Central Precocious Puberty
- Trial name
- NCT07710430
- Testing
- Leuprorelin
- Where
- South Korea
- Volunteers
- 43 people
- Sponsor
- LG Chem
Congenital Adrenal Hyperplasia
Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy
This study is an open-label, randomised, titration-blinded, parallel arm, multicenter study to compare twice daily Chronocort® with standard care in participants with Congenital Adrenal Hyperplasia (CAH).
- Trial name
- RESTORE (NCT03532022)
- Testing
- Chronocort®, Standard Care
- Where
- United States
- Sponsor
- Neurocrine UK Limited
Fallopian Tube Cancer, Ovarian Cancer
Early Chemotherapy Based on CA 125 Level Alone Compared With Delayed Chemotherapy in Treating Patients With Recurrent Ovarian Epithelial , Fallopian Tube, or Primary Peritoneal Cancer
RATIONALE: It is not yet known if treatment for recurrent ovarian epithelial, fallopian tube, or primary peritoneal cancer is more effective if it is begun when blood levels of CA 125 become elevated rather than waiting for other…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00002895
- Testing
- chemotherapy
- Where
- 21 sites in Austria, Belgium and 8 more
- Volunteers
- 1,400 people
- Sponsor
- Medical Research Council
Central Precocious Puberty
Evaluate the Efficacy and Safety of DWJ108J
This study aims to evaluate the efficacy and safety of DWJ108J (Leuprorelin acetate 11.25 mg) in patients with central precocious puberty.
- Trial name
- NCT06025409
- Testing
- Leuprolide Acetate 11.25 MG/ML
- Where
- South Korea
- Volunteers
- 79 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Growth Disorders
Pilot Study of the Effect of Baclofen and Bromocriptine on Luteinizing Hormone Secretion in Pubertal Children
OBJECTIVES: I. Evaluate the effect of bromocriptine on luteinizing hormone (LH) secretion by suppression of prolactin and stimulation of dopaminergic receptors in early pubertal boys and girls. II.
- Trial name
- NCT00004793
- Volunteers
- 4 people
- Sponsor
- National Center for Research Resources (NCRR)
Anorexia Nervosa
Adrenal and Gonadal Hormone Replacement in Anorexia Nervosa
This study seeks to gain new information on why young women with anorexia nervosa are predisposed to early bone loss and osteoporosis.
- Trial name
- NCT00310791
- Testing
- Hormone replacement therapy (estrogen/progestin), Dehydroepiandrosterone (DHEA)
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Boston Children's Hospital
Polycystic Ovary Syndrome, Obesity
Two Different Dietary Interventions for Girls With Polycystic Ovary Syndrome
This study was conducted to evaluate the efficacy of the MEtabolic Syndrome REduction in NAvarra (RESMENA) diet versus a control diet based on American Heart Association (AHA) recommendations for the treatment of PCOS in…
- Conditions
- Polycystic Ovary Syndrome, Obesity, Androgen; Hypersecretion, Diet, Healthy
- Trial name
- NCT05768724
- Testing
- intervention diet, control diet
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Gazi University
Haematological Malignancy, Malignant Neoplasm
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
This clinical trial is looking at two drugs called dabrafenib and trametinib. Dabrafenib and trametinib are approved as standard of care treatment for adult patients with melanoma (a type of skin cancer) or lung cancer and in…
- Conditions
- Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT07440290)
- Testing
- Dabrafenib, Trametinib
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK